Profile data is unavailable for this security.
About the company
Eisai Co., Ltd. is a Japan-based pharmaceutical company mainly engaged in the research and development, manufacture, sale, import and export of pharmaceuticals. The Company operates in two business segments. The Pharmaceutical segment is engaged in the research, development, manufacture and sale of pharmaceuticals for medical use, generic drugs, general medicines, among others. The segment operates in five regions including Japan, Americas (North America), China, EMEA (Europe, Middle East, Africa, Oceania), Asia and Latin America (South Korea, Taiwan, Hong Kong, India, ASEAN, Latin America). The Others segment is involved in license revenues and pharmaceutical raw materials business. The Company is also engaged in the provision of brands such as the anticancer drugs Lembima and Halaven on the nerve and oncology areas.
- Revenue in JPY (TTM)733.85bn
- Net income in JPY32.65bn
- Incorporated1941
- Employees11.07k
- LocationEisai Co LtdEisai Main Bldg., 4-6-10, KoishikawaBUNKYO-KU 112-8088JapanJPN
- Phone+81 338173700
- Fax+81 338113305
- Websitehttps://www.eisai.co.jp/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Santen Pharmaceutical Co Ltd | 304.35bn | 26.85bn | 683.04bn | 3.74k | 25.10 | 2.18 | 14.93 | 2.24 | 74.76 | 74.76 | 844.65 | 862.32 | 0.7155 | 2.68 | 3.25 | 81,289,260.00 | 6.32 | 3.31 | 7.84 | 4.10 | 58.85 | 59.73 | 8.84 | 5.21 | 2.03 | 5.27 | 0.1604 | 82.21 | 8.22 | 5.23 | 278.09 | -3.58 | 5.10 | 4.88 |
Rohto Pharmaceutical Co Ltd | 278.03bn | 30.33bn | 820.96bn | 7.26k | 26.22 | 3.08 | 20.76 | 2.95 | 132.56 | 132.56 | 1,215.22 | 1,129.95 | 0.7642 | 2.21 | 4.37 | 38,300,730.00 | 8.42 | 8.54 | 11.70 | 11.79 | 57.76 | 58.59 | 11.02 | 10.30 | 1.27 | -- | 0.1513 | 19.39 | 13.48 | 8.09 | 17.28 | 25.85 | 5.20 | 18.61 |
Ono Pharmaceutical Co Ltd | 500.33bn | 120.95bn | 1.08tn | 3.85k | 8.50 | 1.25 | 7.73 | 2.15 | 253.57 | 253.57 | 1,052.07 | 1,726.26 | 0.5117 | 2.44 | 3.65 | 129,855,200.00 | 12.38 | 11.95 | 15.14 | 13.73 | 74.69 | 74.11 | 24.20 | 23.89 | 1.32 | -- | 0.1661 | 32.25 | 12.41 | 11.73 | 13.53 | 19.95 | -6.79 | 12.20 |
Kyowa Kirin Co Ltd | 476.00bn | 97.32bn | 1.80tn | 5.97k | 18.31 | 2.03 | 14.88 | 3.77 | 181.56 | 181.56 | 888.29 | 1,634.73 | 0.4645 | 1.61 | 4.01 | 79,678,100.00 | 9.50 | 6.28 | 10.98 | 7.08 | 74.03 | 75.45 | 20.45 | 14.96 | 3.02 | -- | 0.0285 | 47.25 | 11.01 | 10.25 | 51.55 | 10.52 | 10.28 | 9.86 |
Eisai Co Ltd | 733.85bn | 32.65bn | 1.81tn | 11.07k | 53.73 | 1.95 | 24.49 | 2.47 | 113.89 | 113.89 | 2,559.71 | 3,134.76 | 0.5385 | 0.8878 | 3.72 | 66,309,300.00 | 2.52 | 5.29 | 3.32 | 7.16 | 79.40 | 76.91 | 4.69 | 8.68 | 1.74 | -- | 0.1655 | 74.13 | -0.3561 | 2.90 | -23.50 | -7.72 | -2.11 | 1.30 |
Shionogi & Co Ltd | 423.36bn | 150.11bn | 2.02tn | 4.96k | 13.06 | 1.52 | 12.05 | 4.77 | 521.10 | 521.10 | 1,472.49 | 4,492.57 | 0.3011 | 0.9201 | 3.55 | 85,371,040.00 | 10.57 | 12.57 | 11.85 | 14.24 | 86.08 | 84.43 | 35.12 | 37.91 | 5.69 | -- | 0.0092 | 26.77 | 1.97 | 3.41 | -12.40 | 3.38 | 2.17 | 11.22 |
Astellas Pharma Inc | 1.70tn | 21.52bn | 3.29tn | 14.75k | 153.03 | 1.94 | 15.93 | 1.93 | 11.87 | 11.87 | 946.90 | 936.63 | 0.521 | 1.38 | 3.24 | 115,345,400.00 | 0.6587 | 4.59 | 1.03 | 6.61 | 81.51 | 80.53 | 1.26 | 7.98 | 0.7167 | 21.19 | 0.3719 | 86.61 | 5.60 | 4.19 | -82.73 | -40.17 | 9.62 | 13.00 |
Otsuka Holdings Co Ltd | 2.18tn | 126.82bn | 4.77tn | 34.39k | 36.61 | 1.77 | 20.21 | 2.19 | 233.68 | 233.68 | 4,016.84 | 4,829.27 | 0.6256 | 2.34 | 4.50 | 63,393,040.00 | 3.76 | 4.80 | 4.70 | 5.88 | 70.66 | 68.21 | 6.01 | 8.36 | 1.66 | -- | 0.0851 | 42.16 | 16.14 | 9.33 | -9.18 | 8.07 | 9.27 | 1.92 |
Takeda Pharmaceutical Co Ltd | 4.41tn | 149.92bn | 6.89tn | 49.28k | 46.08 | 0.8718 | 7.67 | 1.56 | 94.03 | 94.03 | 2,798.45 | 4,970.05 | 0.2845 | 1.26 | 5.70 | 89,550,420.00 | 0.9677 | 1.65 | 1.15 | 1.97 | 66.18 | 68.05 | 3.40 | 6.06 | 0.7427 | 2.63 | 0.4127 | 128.42 | 5.87 | 15.25 | -54.56 | 1.28 | 29.09 | 0.8735 |
Holder | Shares | % Held |
---|---|---|
Wellington Management Co. LLPas of 31 Jul 2024 | 20.31m | 6.85% |
Nomura Asset Management Co., Ltd.as of 31 Jul 2024 | 17.32m | 5.84% |
The Vanguard Group, Inc.as of 08 Aug 2024 | 9.09m | 3.07% |
Nikko Asset Management Co., Ltd.as of 29 Sep 2023 | 8.43m | 2.84% |
Daiwa Asset Management Co. Ltd.as of 31 Jul 2024 | 8.04m | 2.71% |
Sumitomo Mitsui Trust Asset Management Co., Ltd.as of 29 Sep 2023 | 7.92m | 2.67% |
BlackRock Fund Advisorsas of 08 Aug 2024 | 5.18m | 1.75% |
Mitsubishi UFJ Asset Management Co., Ltd.as of 08 Aug 2024 | 4.51m | 1.52% |
Norges Bank Investment Managementas of 31 Dec 2023 | 3.98m | 1.34% |
Geode Capital Management LLCas of 22 Aug 2024 | 2.54m | 0.86% |